Oric Pharmaceuticals, Inc. · Brief

Next report

10 days

Nov 12 · after closeest.Q3 FY26

Expected move

No implied move.

8 reportsHistory

0 of 8≥ implied

Nov 12 '24±9.3%▲+0.10%×0.01

Feb 18 '25±7.0%▲+1.15%×0.17

May 5 '25±64.1%▼−11.58%×0.18

Aug 12 '25±11.3%▲+3.26%×0.29

Nov 13 '25±31.1%▲+0.49%×0.02

Feb 23 '26±40.3%▲+14.60%×0.36

Q1 FY26±47.2%▼−0.62%×0.01

Q2 FY26±44.4%▲+27.08%×0.61

quarterimplied−65%0+65%realized×

Q2 FY26±44.4%▲+27.08%×0.61

Q1 FY26±47.2%▼−0.62%×0.01

Feb '26±40.3%▲+14.60%×0.36

Nov '25±31.1%▲+0.49%×0.02

Aug '25±11.3%▲+3.26%×0.29

May '25±64.1%▼−11.58%×0.18

2 older reports

Feb '25±7.0%▲+1.15%×0.17

Nov '24±9.3%▲+0.10%×0.01

Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close

Nov 12 report · est.

Bull2 of 4

5disclosed supplier and customer ties in SEC filings across multiple counterpartiesSEC filings

180managers reporting a position in the latest quarterly filings worldwide13F · Jun 30 '26

Bear2 of 4

8 of 8recent reports where the move came in under the options implied rangeEarnings history

0.33%of State Street SPDR S&P Biotech ETF's assets, the largest tracked-fund weightN-PORT · Jun 30 '26

AI captions · Sep 28 '26once per report · top 2 per case

ORIC report session

No linked exposure.

Oct 29impliedImplied move: ±55.3% into Nov 12 earnings (Oct 29 close).Source

privateThesis 0 · Decisions 0 · Observations 0

No thesis.